Efficacy and safety of new direct oral anticoagulants in chronic kidney disease: AHA 2019 updated guidelines and review of the literature

• Päätekijät: Hubert Stępak (Tekijä), Zbigniew Krasiński (Tekijä), Andrzej Jawień (Tekijä), Navid Ahmadi (Tekijä), Adam Lipowski (Tekijä), Michał Stanisic (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Termedia Publishing House, 2020-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Direct oral anticoagulants (DOACs) are the drug of choice for the treatment of atrial fibrillation-associated systemic embolism and reducing the risk of strokes in chronic kidney disease (CKD) patients. DOACs have fewer drug-to-drug interactions as well as fewer side effects, compared to warfarin. T...